News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB) (JOBS) To Discontinue Rheumatoid Arthritis Drug As Drug Fails To Meet Primary, Secondary Endpoints


10/9/2008 4:59:18 PM

(RTTNews) - Thursday, Biogen Idec said its rheumatoid arthritis drug candidate baminercept failed to meet both primary and secondary endpoints in its Phase II trial and added that it would discontinue the development of the compound in rheumatoid arthritis.

Read at RTT News
Read at Reuters
Read at AP

comments powered by Disqus
RTT News
Reuters
AP
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES